RNhale
RNhale is developing a next-generation inhalable therapy based on RNA technology, specifically utilizing RNA interference (RNAi) for gene silencing. Their platform allows for the precise delivery of RNAi molecules like siRNAs, ASOs, and miRNAs directly to the lungs to target and treat diseases characterized by overexpressed genes. The company employs AI-powered lipid nanoparticle (LNP) formulation to customize delivery for specific diseases, enhancing targeting and effectiveness. Their proprietary NEM (Nano-Embedded-Microparticle) technology embeds LNPs within inhalable microparticles, resulting in a stable, room-temperature product suitable for large-scale, cost-effective production. Dry powder inhalation enhances patient convenience and compliance through self-administration. RNhale has received a €2.5 million EIC Transition Grant for its ARISE project, focused on developing a dry powder RNA therapeutic for severe asthma, which aims to accelerate preclinical development towards clinical readiness.
RNhale
RNhale is developing a next-generation inhalable therapy based on RNA technology, specifically utilizing RNA interference (RNAi) for gene silencing. Their platform allows for the precise delivery of RNAi molecules like siRNAs, ASOs, and miRNAs directly to the lungs to target and treat diseases characterized by overexpressed genes. The company employs AI-powered lipid nanoparticle (LNP) formulation to customize delivery for specific diseases, enhancing targeting and effectiveness. Their proprietary NEM (Nano-Embedded-Microparticle) technology embeds LNPs within inhalable microparticles, resulting in a stable, room-temperature product suitable for large-scale, cost-effective production. Dry powder inhalation enhances patient convenience and compliance through self-administration. RNhale has received a €2.5 million EIC Transition Grant for its ARISE project, focused on developing a dry powder RNA therapeutic for severe asthma, which aims to accelerate preclinical development towards clinical readiness.